The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
MERCK

Sample Resistance Reports

When you see these protease mutations on a genotypic report, how can you be sure you're not overlooking a potentially active agent?

Take a look at the latest resistance analysis reports from Monogram and Virco. These reports show how various known mutations affect specific therapeutic options. New reports are posted quarterly; check back regularly for updated information.

virco®TYPE HIV-I
Resistance Analysis Profiles

Sample Report 1A
Mutations in this sample report:

NRTI/NtRTI:
41L, 184V, 211K, 215Y
NNRTI:
135T
PI:
35D, 63P, 71T, 84V, 90M, 93L

PhenoSense GT™ HIV-I
Resistance Analysis Profiles

Sample Report 1B
Mutations in this sample report:

NRTI/NtRTI:
M184V
NNRTI:
none
PI:
L10L/F, K20R, L33F, M36I, M46I, I50L, F53L, L63P, V82A

Sample Report 2A
Mutations in this sample report:

NRTI/NtRTI:
20R, 41L, 215F, 228R
NNRTI:
103S, 106A, 190A
PI:
46I, 50V, 63P, 93L
 
 

Sample Report 2B
Mutations in this sample report:

NRTI/NtRTI:
M41L, L74V, T215F
NNRTI:
YI88L
PI:
I13V, K20K/R, L33F, K43T, M46L, I50L, L63P, G73S, V77I
New profiles will be added in August 2006.

IMPORTANT SELECTED RISK INFORMATION


Contraindications

CRIXIVAN is contraindicated in patients with clinically significant hypersensitivity to any of its components.

Drugs That Should Not Be Coadministered With CRIXIVAN
Drug Class Drug Name Clinical Comment
Antiarrhythmics* Amiodarone CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Ergot derivatives* Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.
Sedative/hypnotics* Midazolam, triazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.
GI motility agents* Cisapride CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Neuroleptics* Pimozide CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Herbal products St. John’s wort
(Hypericum perforatum) and products containing St. John’s wort		 May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.
Antimycobacterial Rifampin May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.
HMG-CoA reductase inhibitors Lovastatin, simvastatin Potential for serious reactions such as risk of myopathy, including rhabdomyolysis, may be increased.
Protease inhibitor Atazanavir Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia. Combinations of these drugs have not been studied, and coadministration of CRIXIVAN and atazanavir is not recommended.

*
Inhibition of CYP3A4 by CRIXIVAN could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.

Selected Warnings

ALERT: Find out about medicines that should NOT be taken with CRIXIVAN.

Nephrolithiasis/urolithiasis has occurred in clinical studies in adult patients (12.4%; range across individual trials, 4.7% to 34.4%) and in pediatric patients (29%) receiving CRIXIVAN. The cumulative frequency of nephrolithiasis events increases with increasing exposure to CRIXIVAN; however, the risk over time remains relatively constant. In some cases, nephrolithiasis/urolithiasis has been associated with renal insufficiency or acute renal failure and pyelonephritis with or without bacteremia. If signs or symptoms of nephrolithiasis/urolithiasis occur (including flank pain with or without hematuria or microscopic hematuria), temporary interruption (eg, 1 to 3 days) or discontinuation of therapy may be considered. Adequate hydration (at least 48 ounces daily for adults) is recommended in all patients treated with CRIXIVAN.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

CRIXIVAN is a registered trademark of Merck & Co., Inc. Other brands listed are the trademarks of their respective owners and are not trademarks of Merck & Co., Inc.
20651055(3)-05/06-CRX